NBIX Neurocrine Biosciences, Inc. - Common Stock
NASDAQ · Biotechnology · 在 SEC EDGAR 上查看 ↗ 收盘 十月 2, 2026 10-K/10-Q 七月 31, 2026
$143.18
· % 处于52周区间
· 高于低点
· 至高点
$123.0052周低点
$186.1252周高点
市值 (MRQ)
$14.55B
P/E (TTM)
21.0
EPS (TTM)
$6.83
收入 (TTM)
$3.37B
NBIX 股票快照 价格、市值、P/E、EPS、ROE、负债/权益、52周范围
价格
$143.18
市值 (MRQ)
$14.55B
P/E (TTM)
21.0
EPS (TTM)
$6.83
收入 (TTM)
$3.37B
ROE (TTM)
22.1%
52周区间
$123–$186
NBIX 股价图表 包含技术指标的日 OHLCV — 平移、缩放和自定义您的视图
区间
条形图
柱状图粒度会根据所选周期进行调整 — 将鼠标悬停在图表上可查看柱状图的开盘价/最高价/最低价/收盘价。
关于 Neurocrine Biosciences, Inc. - Common Stock 公司概况（来自维基百科）
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD).
The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids.
History
Neurocrine was founded in San Diego, California, in 1992. The company's academic founders were Wylie Vale of the Salk Institute for Biological Studies, and Lawrence Steinman of Stanford University. The company was backed and organized by Larry Bock of Avalon Ventures among others.
In 1995, the company collaborated with Belgium-based Janssen Pharmaceutica N.V. to develop treatments for psychiatric disorders utilizing corticotropin releasing factor (CRF) antagonists, a class of compounds to treat psychiatric, neurological and gastrointestinal diseases including anxiety, depression and irritable bowel syndrome. The company underwent an IPO in May 1996, listing on the NASDAQ exchange under the symbol NBIX and raising $34.2 million.
In October 1996, Eli Lilly and Company agreed to pay Neurocrine $74 million over five years to develop drugs for obesity and Alzheimer's disease based on its research of CRF-binding protein-ligand inhibitors.
In July 2001, Neurocrine and GlaxoSmithKline entered into a worldwide research, development and commercialization agreement, including a collaborative research program for up to five years to identify and develop CRF-R antagonist compounds. The collaboration also included worldwide development and commercialization of NBI-34041 as well as potential backup candidates resulting from the research program. Neurocrine received upfront fees and early milestone payments totaling $25.5 million.
In December 2002, Neurocrine reached an agreement with Pfizer for the rights to its experimental insomnia drug, indiplon. The deal paid Neurocrine $100 million initially with a possible $300 million more if the drug met regulatory and sales goals. In May 2006, the FDA issued a non-approvable letter for a modified-release 15 mg formulation of indiplon and an approvable letter with stipulations for 5 mg and 10 mg immediate-release formulations. As a result, Pfizer terminated its agreement with Neurocrine. Following a resubmission of the 5 mg and 10 mg formulations in December 2007, Neurocrine's new drug application was deemed 'approvable' but the FDA requested additional studies. The company discontinued development of the drug in the United States. In 2007, Neurocrine partnered with Dainippon Sumitomo Pharma to develop and commercialize indiplon in Japan. The deal paid Neurocrine $20 million up front with the ability to receive milestone payments and royalties based on the commercialization of indiplon in Japan.
Kevin Gorman replaced Gary Lyons as CEO of the company in January 2008. Lyons was CEO and president of the company since its founding and maintained a role on the company's board of directors.
On June 16, 2010, Neurocrine agreed to a deal with AbbVie Inc. (previously Abbott Laboratories) worth up to $575 million with Neurocrine granting AbbVie the worldwide rights to develop and commercialize elagolix, an oral gonadotropin-releasing hormone (GnRH) antagonist to treat endometriosis and uterine fibroids. The deal paid Neurocrine $75 million up front.
In April 2017, the FDA approved valbenazine for the treatment of TD. At the time of approval, it was the first and only drug approved for adults with TD. Neurocrine is also studying valbenazine in clinical trials for the treatment of Tourette Syndrome. In October 2017, Neurocrine announced that it had been granted orphan drug designation status from the FDA for valbenazine for the treatment of pediatric patients with Tourette syndrome.
In February 2017, Neurocrine announced an exclusive licensing agreement for the development and commercialization of the Parkinson's disease drug, opicapone, in North America with the Portugal-based pharmaceutical company Bial. As part of the agreement, Neurocrine provided an upfront payment of $30 million and agreed to fund development activities for FDA approval in the United States. Bial is eligible to receive additional milestone payments of up to $115 million and a percentage of net sales.
In September 2017, AbbVie submitted a NDA to the FDA for elagolix for the management of endometriosis and associated pain. The submission was supported by two similar Phase 3 clinical studies involving 1,700 women. In October 2017, AbbVie and Neurocrine announced that the FDA granted priority review for the elagolix NDA. A final regulatory decision on the drug will come during the third quarter of 2018. The companies are also developing elagolix for the treatment of uterine fibroids which is in Phase III development.
In 2021,Nexera Pharmain Japan licensed out its investigational schizophrenia drug, NBI-1117568, to Neurocrine Biosciences for development.
In August 2024, Neurocrine announced the results of a Phase II clinical trial of NBI-1117568 . The drug demonstrated a 7.5-point improvement in the Positive and Negative Syndrome Scale (PANSS), which was lower than the 8.4-point improvement seen with KarXT (developed by Karuna Therapeutics) and the 12.7-point improvement seen with Emraclidine (developed by Cerevel Therapeutics), both of which were also in clinical trials at the time. Additionally, the study found no dose-dependent response to NBI-1117568. As a result, Neurocrine's stock price fell 19% the following day as investors were disappointed by the results.
Product pipeline
Elagolix – gonadotropin-releasing hormone receptor antagonist undergoing FDA review for the treatment of endometriosis and in clinical trials for uterine fibroids
Opicapone – A once daily catechol-O-methyl transferase inhibitor in trials for Parkinson's disease
NBI-74788 – Corticotropin-releasing factor (CRF) receptor antagonist
NBI-1117568 - A drug that stimulates muscarinic receptors and is used to treat schizophrenia.
来源：维基百科 (英语), CC BY-SA 4.0 · 在维基百科上查看 ↗
行业板块Healthcare
行业Biotechnology
员工2500
国家US
10年表现 收入、净利润、利润率和每股收益趋势
收入$2.86B2016-12-31 → 2025-12-31
EPS$4.672016-12-31 → 2025-12-31
自由现金流$749M2016-12-31 → 2025-12-31
净利率20.9%2016-12-31 → 2025-12-31
估值与比率
估值 P/E、P/S、P/B、EV/EBITDA 比率 — 该股票是昂贵还是便宜？
| 指标 | 5年趋势 | NBIX | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| P/E (TTM) | 21.05年均值 ≈58.9 | ≈58.9 | 19.4 | 估值过高 | |
| P/S (TTM) | 4.35年均值 ≈6.5 | ≈6.5 | 7.3 | 低估 | |
| 市净率 (MRQ) | 3.95年均值 ≈5.6 | ≈5.6 | 14.5 | 低估 | |
| 股价/自由现金流 (TTM) | 16.75年均值 ≈29.9 | ≈29.9 | · | · | |
| 市现率 (TTM) | 16.25年均值 ≈28.0 | ≈28.0 | 13.6 | 估值过高 | |
| 市净率（有形资产） (MRQ) | 9.95年均值 ≈5.7 | ≈5.7 | · | · | |
| PEG Ratio (市盈率增长比) | ≈9.0 | · | · | · |
同行中位数按每项指标的标准化基础计算，可能与本股票显示的TTM/MRQ基础不完全匹配。
盈利能力 毛利率、营业利润率和净利率；股本回报率 (ROE)、资产回报率 (ROA)、投入资本回报率 (ROIC)
| 指标 | 5年趋势 | NBIX | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| 营业利润率 (TTM) | 23.6%5年均值 ≈17.0% | ≈17.0% | 15.8% | 持平 | |
| EBITDA Margin (息税折旧摊销前利润率) | 21.6%5年均值 ≈17.0% | ≈17.0% | 15.8% | 持平 | |
| 税前利润率 (TTM) | 27.9%5年均值 ≈17.2% | ≈17.2% | 16.9% | 持平 | |
| 净利润率 (TTM) | 20.9%5年均值 ≈12.5% | ≈12.5% | 15.1% | 持平 | |
| ROA (TTM) | 15.3%5年均值 ≈8.4% | ≈8.4% | -0.46% | 顶尖 | |
| ROE (TTM) | 22.1%5年均值 ≈11.4% | ≈11.4% | 17.4% | 持平 | |
| ROIC | 12.9%5年均值 ≈10.8% | ≈10.8% | 14.5% | 弱 |
财务健康 债务、流动性、偿付能力 — 资产负债表强度
| 指标 | 5年趋势 | NBIX | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| 流动比率 (MRQ) | 1.95年均值 ≈3.2 | ≈3.2 | 3.3 | 低流动性 | |
| Quick Ratio (速动比率) | 1.95年均值 ≈1.8 | ≈1.8 | 2.5 | 低流动性 |
成长 营收、每股收益 (EPS) 和净利润增长：同比、3年复合年增长率 (CAGR)、5年复合年增长率 (CAGR)
| 指标 | 5年趋势 | NBIX | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| Revenue YoY (营收同比增长) | 21.4%5年均值 ≈22.5% | ≈22.5% | · | · | |
| Revenue CAGR 3Y (营收3年复合年增长率) | 24.3%5年均值 ≈24.6% | ≈24.6% | · | · | |
| Revenue CAGR 5Y (营收5年复合年增长率) | 22.3% | · | · | · | |
| EPS YoY | 41.9%5年均值 ≈25.0% | ≈25.0% | · | · | |
| Net Income YoY (净利润同比增长) | 40.2%5年均值 ≈26.6% | ≈26.6% | · | · | |
| EPS CAGR 3Y (每股收益年复合增长率（3年）) | 44.1%5年均值 ≈27.0% | ≈27.0% | · | · | |
| EPS CAGR 5Y (每股收益年复合增长率（5年）) | 2.3% | · | · | · | |
| Net Income CAGR 3Y (净利润年复合增长率（3年）) | 45.8%5年均值 ≈29.0% | ≈29.0% | · | · | |
| Net Income CAGR 5Y (净利润年复合增长率（5年）) | 3.3% | · | · | · |
资本效率 资产周转率、库存周转率、应收账款周转率
| 指标 | 5年趋势 | NBIX | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| Asset Turnover (资产周转率) | 0.75年均值 ≈0.7 | ≈0.7 | 0.6 | 持平 | |
| Inventory Turnover (库存周转率) | 0.85年均值 ≈0.8 | ≈0.8 | 1.6 | 弱 | |
| Receivables Turnover (应收账款周转率) | 4.95年均值 ≈5.4 | ≈5.4 | 7.0 | 弱 | |
| Revenue / Employee (年营业收入 ÷ 员工人数（报告的 headcount，yfinance）。衍生数据 — 非存储的 SEC-XBRL 概念。) | ≈$1.1M | · | · | · |
价值 · ≈ 5年均值 · 行业中值 · 相对于中值的评判
收益历史 每股收益实际值 vs 预估值，惊喜%，达标率，下次财报日期
平均惊喜
11.3%
下次报告
十月 26, 2026
| 期间 | 报告 | EPS Actual | EPS 预期 | 惊喜 |
|---|---|---|---|---|
| 2026年6月30日 | 七月 28, 2026 | $1.39 | $1.37 | 1.5% |
| 2026年3月31日 | $1.91 | $1.20 | 59.5% | |
| 2025年12月31日 | $1.91 | $1.20 | 59.5% | |
| 2025年9月30日 | $2.04 | $1.62 | 26.1% | |
| 2025年6月30日 | $1.06 | $0.99 | 7.0% | |
| 2025年3月31日 | $0.08 | $0.56 | -85.6% |
完整基本面 所有年度指标 — 损益表、资产负债表、现金流量表
损益表
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.86B | $2.36B | $1.89B | $1.49B | $1.13B | $1.05B | $788M | $451M | $162M | $15M | $20M | $0 | |
| Cost of Revenue | $52M | $34M | $40M | $23M | $14M | $10M | · | $5M | $1M | $0 | $0 | · | |
| R&D Expense | · | · | · | · | · | · | · | $161M | $122M | $94M | $81M | $46M | |
| SG&A Expense | $1.16B | $1.01B | $888M | $753M | $583M | $433M | $354M | $249M | $170M | $68M | $32M | $18M | |
| Operating Expenses | $2.24B | $1.78B | $1.64B | $1.24B | $1.03B | $883M | $716M | $414M | $293M | $162M | $114M | $64M | |
| Operating Income | $619M | $570M | $251M | $249M | $102M | $163M | $72M | $37M | $-131M | $-147M | $-94M | $-64M | |
| Interest Expense | · | · | $5M | $7M | $26M | $33M | $32M | $30M | $20M | $0 | $0 | · | |
| Interest Income | · | · | · | · | · | · | · | · | · | $3M | $2M | $629.0K | |
| Other Non-op | $86M | $-84M | $81M | $-35M | $-1M | $-56M | $-26M | $-15M | $-11M | $6M | $20.0K | $18.0K | |
| Pretax Income | $705M | $486M | $332M | $214M | $101M | $107M | $46M | $22M | $-143M | $-141M | · | · | |
| Income Tax | $227M | $145M | $82M | $59M | $12M | $-301M | $10M | $700.0K | $0 | $0 | $0 | $0 | |
| Net Income | $479M | $341M | $250M | $154M | $90M | $407M | $37M | $21M | $-143M | $-141M | $-89M | $-61M | |
| EPS (Basic) | $4.81 | $3.40 | $2.56 | $1.61 | $0.95 | $4.38 | $0.40 | $0.23 | $-1.62 | $-1.63 | $-1.05 | $-0.81 | |
| EPS (Diluted) | $4.67 | $3.29 | $2.47 | $1.56 | $0.92 | $4.16 | $0.39 | $0.22 | $-1.62 | $-1.63 | $-1.05 | $-0.81 | |
| Shares (Basic) | 99,500,000 | 100,400,000 | 97,700,000 | 95,800,000 | 94,600,000 | 93,100,000 | 91,600,000 | 90,200,000 | 88,089,000 | 86,713,000 | 84,496,000 | 74,577,000 | |
| Shares (Diluted) | 102,500,000 | 103,700,000 | 101,000,000 | 98,900,000 | 97,900,000 | 97,800,000 | 95,700,000 | 95,400,000 | 88,089,000 | 86,713,000 | 84,496,000 | 74,577,000 | |
| EBITDA | $619M | $570M | $251M | $249M | $102M | $163M | $72M | $37M | $-131M | $-147M | · | $-64M |
资产负债表
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $713M | $233M | $251M | $263M | $341M | $187M | $112M | $142M | $255M | $83M | $74M | $31M | |
| Short-term Investments | · | · | · | · | $370M | $614M | $558M | $509M | $261M | $224M | $305M | $163M | |
| Receivables | $687M | $479M | $439M | $350M | $186M | $157M | $127M | $57M | $31M | $0 | · | · | |
| Inventory | $69M | $57M | $38M | $35M | $30M | $28M | $17M | $11M | $1M | $0 | · | · | |
| Prepaid Expense | $171M | $48M | · | · | · | · | · | · | · | · | · | · | |
| Other Current Assets | $116M | $64M | $98M | $79M | $46M | $30M | $17M | $19M | $7M | $3M | $5M | $4M | |
| Current Assets | $2.52B | $1.72B | $1.61B | $1.45B | $973M | $1.02B | $831M | $738M | $555M | $310M | $384M | $198M | |
| PP&E (Net) | $90M | $83M | $71M | $59M | $59M | $45M | $42M | $34M | $11M | $6M | $3M | $3M | |
| PP&E (Gross) | $208M | $189M | $154M | $125M | $110M | $86M | $76M | $62M | $38M | $32M | $30M | $31M | |
| Accum. Depreciation | $118M | $106M | $83M | $66M | $52M | $42M | $34M | $28M | $28M | $26M | $27M | $29M | |
| Goodwill | $6M | $6M | $6M | $5M | $0 | · | · | · | · | · | · | · | |
| Intangibles | $5M | $36M | $36M | $37M | $0 | · | · | · | · | · | · | · | |
| Other Non-current Assets | $49M | $52M | $50M | $25M | $4M | $6M | $0 | · | · | · | · | · | |
| Total Assets | $4.63B | $3.72B | $3.25B | $2.37B | $2.07B | $1.73B | $1.31B | $993M | $818M | $365M | $475M | $243M | |
| Accounts Payable | $674M | $462M | $449M | $348M | $226M | $169M | $141M | $86M | $6M | $5M | $3M | $246.0K | |
| Accrued Liabilities | · | · | · | · | · | · | · | · | · | $21M | $19M | $12M | |
| Current Liabilities | $743M | $508M | $655M | $538M | $246M | $186M | $565M | $88M | $54M | $30M | $26M | $16M | |
| Capital Leases | $415M | $455M | $258M | $94M | $105M | $94M | $87M | $0 | · | · | · | · | |
| Deferred Tax | $0 | · | · | · | · | · | · | · | · | · | · | · | |
| Other Non-current Liabilities | $220M | $166M | $106M | $30M | $12M | $10M | $17M | $36M | $0 | $113.0K | $221.0K | $260.0K | |
| Total Liabilities | $1.38B | $1.13B | $1.02B | $661M | $698M | $608M | $669M | $512M | $445M | $50M | $50M | $34M | |
| Common Stock | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $91.0K | $89.0K | $87.0K | $86.0K | $76.0K | |
| Paid-in Capital | · | · | · | · | · | · | · | · | · | · | · | $1.04B | |
| Retained Earnings | $448M | $29M | $-157M | $-407M | $-636M | $-725M | $-1.13B | $-1.18B | $-1.20B | $-1.06B | $-915M | $-826M | |
| AOCI | $13M | $6M | $7M | $-8M | $-2M | $2M | $1M | $-2M | $-2M | $-318.0K | $-977.0K | $-277.0K | |
| Stockholders' Equity | $3.25B | $2.59B | $2.23B | $1.71B | $1.37B | $1.13B | $637M | $481M | $372M | $315M | $424M | $209M | |
| Liabilities + Equity | $4.63B | $3.72B | $3.25B | $2.37B | $2.07B | $1.73B | $1.31B | $993M | $818M | $365M | $475M | $243M | |
| Shares Outstanding | 100,100,000 | 99,400,000 | 98,700,000 | 96,500,000 | 94,900,000 | 93,500,000 | 92,300,000 | 90,797,000 | 88,793,903 | 86,883,300 | 86,262,594 | 76,465,942 |
现金流
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | · | $4M | $2M | $1M | $1M | $827.0K | |
| Stock-based Comp | $218M | $196M | $194M | $173M | $134M | $100M | $75M | $58M | $43M | $28M | $28M | $10M | |
| Deferred Tax | $164M | $-123M | $-61M | $22M | $6M | $-311M | $0 | $0 | · | · | · | · | |
| Amort. of Intangibles | $4M | $4M | $4M | $500.0K | $0 | $0 | · | · | · | · | · | · | |
| Operating Cash Flow | $783M | $595M | $390M | $339M | $256M | $228M | $147M | $101M | $-94M | $-106M | $-38M | $-47M | |
| CapEx | $34M | $38M | $28M | $16M | $23M | $11M | $15M | $25M | $7M | $4M | $2M | $2M | |
| Investing Cash Flow | $-264M | $-127M | $-467M | $-177M | $-130M | $4M | $-211M | $-243M | $-251M | $113M | · | · | |
| Stock Issued | $129M | $122M | $65M | $45M | $28M | $29M | $32M | $30M | $14M | $2M | $277M | $139M | |
| Stock Repurchased | $168M | $300M | $0 | $0 | · | · | · | · | · | · | · | · | |
| Net Stock Activity | $-38M | $-178M | $65M | $45M | $28M | $29M | $27M | $30M | $14M | $2M | · | $139M | |
| Financing Cash Flow | $-38M | $-487M | $65M | $-234M | $27M | $-158M | $32M | $30M | $517M | $2M | · | · | |
| Net Change in Cash | $480M | $-18M | $-12M | $-73M | $154M | $75M | $-32M | $-112M | $171M | $9M | $43M | $-14M | |
| Taxes Paid | $81M | · | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $749M | $557M | $362M | $323M | $233M | $218M | $137M | $77M | $-101M | $-110M | · | $-49M | |
| Levered FCF | · | · | $358M | $318M | $210M | $92M | $112M | $47M | · | · | · | · |
盈利能力
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 21.6% | 24.2% | 13.3% | 16.7% | 9.0% | 15.6% | 9.2% | 8.2% | -81.3% | -982.5% | · | · | |
| Net Margin | 16.7% | 14.5% | 13.2% | 10.4% | 7.9% | 38.9% | 4.7% | 4.7% | -88.2% | -940.6% | · | · | |
| Pretax Margin | 24.7% | 20.6% | 17.6% | 14.4% | 8.9% | 10.2% | 5.9% | 4.8% | · | · | · | · | |
| EBITDA Margin | 21.6% | 24.2% | 13.3% | 16.7% | 9.0% | 15.6% | 9.2% | 8.2% | -81.3% | -982.5% | · | · | |
| ROA | 11.5% | 9.8% | 8.9% | 7.0% | 4.7% | 26.8% | 3.2% | 2.3% | -24.1% | -33.6% | · | -30.4% | |
| ROE | 16.1% | 12.9% | 11.8% | 9.5% | 6.6% | 42.2% | 6.1% | 4.5% | -41.5% | -38.2% | · | -36.8% | |
| ROIC | 12.9% | 15.5% | 8.5% | 10.5% | 6.6% | 55.2% | 9.0% | 7.4% | · | · | · | · |
流动性与偿付能力
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.4 | 3.4 | 2.5 | 2.7 | 4.0 | 5.4 | 1.5 | 8.4 | 10.2 | 10.2 | · | 12.7 | |
| Quick Ratio | 1.9 | 1.4 | 1.1 | 1.1 | 3.6 | 5.1 | 1.4 | 2.2 | 10.1 | 10.1 | · | 12.4 | |
| Interest Coverage | · | · | 54.5 | 35.1 | 4.0 | 5.0 | 2.3 | 1.2 | -6.7 | · | · | · |
效率
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.7 | 0.7 | 0.7 | 0.7 | 0.6 | 0.7 | 0.7 | 0.5 | 0.3 | 0.0 | · | 0.0 | |
| Inventory Turnover | 0.8 | 0.7 | 1.1 | 0.7 | · | · | · | 0.8 | · | · | · | · | |
| Receivables Turnover | 4.9 | 5.1 | 4.8 | 5.6 | 6.6 | 7.4 | 8.6 | 10.3 | 10.4 | · | · | · |
每股
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $32.50 | $26.05 | $22.61 | $17.70 | $14.48 | $12.04 | $6.90 | $5.29 | $4.19 | $3.62 | · | $2.73 | |
| Revenue / Share | $27.91 | $22.71 | $18.68 | $15.05 | $11.58 | $10.69 | $8.23 | $4.73 | $1.83 | $0.17 | · | $0.00 | |
| Cash Flow / Share | $7.64 | $5.74 | $3.86 | $3.43 | $2.62 | $2.34 | $1.59 | $1.06 | $-1.07 | $-1.22 | · | $-0.63 | |
| Cash / Share | $7.12 | $2.34 | $2.54 | $2.72 | $3.59 | $2.00 | $1.22 | $1.56 | $2.87 | $0.96 | · | $0.41 | |
| EPS (TTM) | $4.67 | $3.29 | $2.47 | $1.56 | $0.92 | $4.16 | $0.39 | $0.22 | $-1.62 | $-1.63 | $-1.05 | $-0.81 |
增长率
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 21.4% | 24.8% | 26.8% | 31.3% | 8.4% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 24.3% | 27.6% | 21.7% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 22.3% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 41.9% | 33.2% | 58.3% | 69.6% | -77.9% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | 44.1% | 52.9% | -16.0% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | 2.3% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 40.2% | 36.7% | 61.6% | 72.4% | -78.0% | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 45.8% | 56.2% | -15.0% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | 3.3% | · | · | · | · | · | · | · | · | · | · | · |
估值 (TTM)
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $2.86B | $2.36B | $1.89B | $1.49B | $1.13B | $1.05B | $788M | $451M | $162M | $15M | $20M | $0 | |
| Net Income TTM | $479M | $341M | $250M | $154M | $90M | $407M | $37M | $21M | $-143M | $-141M | $-89M | $-61M | |
| Market Cap | $14.20B | $13.57B | $13.00B | $11.53B | $8.08B | $8.96B | $9.92B | $6.48B | $6.89B | $3.36B | · | $1.71B | |
| P/E | 30.4 | 41.5 | 53.3 | 76.6 | 92.6 | 23.0 | 275.6 | 324.6 | -47.9 | -23.7 | -53.9 | -27.6 | |
| P/S | 5.0 | 5.8 | 6.9 | 7.7 | 7.1 | 8.6 | 12.6 | 14.4 | 42.6 | 224.2 | · | · | |
| P/B | 4.4 | 5.2 | 5.8 | 6.7 | 5.9 | 8.0 | 15.6 | 13.5 | 18.5 | 10.7 | · | 8.2 | |
| P / Tangible Book | 4.4 | 5.3 | 5.9 | 6.9 | 5.9 | 8.0 | · | · | · | · | · | · | |
| P / Cash Flow | 18.1 | 22.8 | 33.4 | 34.0 | 31.5 | 39.2 | 65.2 | 64.0 | -73.0 | -31.7 | · | -36.2 | |
| P / FCF | 19.0 | 24.4 | 36.0 | 35.7 | 34.7 | 41.2 | 72.2 | 84.7 | -68.0 | -30.5 | · | -35.0 | |
| Earnings Yield | 3.3% | 2.4% | 1.9% | 1.3% | 1.1% | 4.3% | 0.36% | 0.31% | -2.1% | -4.2% | -1.9% | -3.6% |
损益表
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $959M | $814M | $806M | $795M | $688M | $573M | $628M | $622M | $590M | $515M | $515M | $499M | $453M | $420M | $412M | $388M | |
| Cost of Revenue | · | $14M | $18M | $14M | $11M | $9M | $9M | $8M | $9M | $8M | $8M | $11M | $12M | $8M | $8M | $6M | |
| SG&A Expense | $440M | $318M | $302M | $292M | $286M | $276M | $288M | $234M | $242M | $243M | $219M | $204M | $222M | $243M | $183M | $186M | |
| Operating Expenses | $808M | $621M | $595M | $556M | $542M | $549M | $486M | $438M | $445M | $416M | $365M | $358M | $379M | $535M | $309M | $300M | |
| Operating Income | $152M | $193M | $211M | $239M | $146M | $24M | $142M | $184M | $145M | $99M | $150M | $141M | $74M | $-114M | $103M | $88M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $1M | · | $1M | $1M | $1M | · | $1M | |
| Other Non-op | $11M | $53M | $28M | $53M | $14M | $-9M | $21M | $6M | $-47M | $-65M | $48M | $-26M | $48M | $11M | $14M | $10M | |
| Pretax Income | $162M | $247M | $239M | $292M | $160M | $15M | $163M | $190M | $99M | $34M | $198M | $116M | $122M | $-103M | $118M | $98M | |
| Income Tax | $18M | $49M | $86M | $82M | $52M | $7M | $60M | $60M | $34M | $-9M | $50M | $32M | $26M | $-27M | $29M | $29M | |
| Net Income | $144M | $198M | $154M | $210M | $108M | $8M | $103M | $130M | $65M | $43M | $148M | $83M | $96M | $-77M | $89M | $68M | |
| EPS (Basic) | $1.43 | $1.97 | $1.53 | $2.11 | $1.09 | $0.08 | $1.05 | $1.28 | $0.64 | $0.43 | $1.52 | $0.85 | $0.98 | $-0.79 | $0.92 | $0.72 | |
| EPS (Diluted) | $1.39 | $1.91 | $1.49 | $2.04 | $1.06 | $0.08 | $1.00 | $1.24 | $0.63 | $0.42 | $1.49 | $0.82 | $0.95 | $-0.79 | $0.91 | $0.69 | |
| Shares (Basic) | 101,000,000 | 100,500,000 | · | 99,400,000 | 99,000,000 | 99,700,000 | · | 101,100,000 | 100,800,000 | 99,800,000 | · | 97,900,000 | 97,600,000 | 97,100,000 | · | 95,800,000 | |
| Shares (Diluted) | 104,200,000 | 103,400,000 | · | 102,500,000 | 101,000,000 | 102,500,000 | · | 104,300,000 | 103,900,000 | 103,600,000 | · | 101,100,000 | 100,200,000 | 97,100,000 | · | 99,000,000 | |
| EBITDA | $152M | $193M | · | $239M | $146M | $24M | · | $184M | $145M | $99M | · | $141M | $74M | $-114M | · | $88M |
资产负债表
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $332M | $266M | $713M | $340M | $264M | $194M | $233M | $349M | $140M | $396M | · | $294M | $160M | $104M | · | $212M | |
| Receivables | $887M | $768M | $687M | $728M | $596M | $516M | $479M | $481M | $468M | $451M | · | $418M | $388M | $392M | · | $301M | |
| Inventory | $104M | $64M | $69M | $69M | $57M | $59M | $57M | $46M | $42M | $37M | · | $29M | $32M | $33M | · | $37M | |
| Prepaid Expense | $217M | $225M | $171M | $178M | · | · | $48M | · | · | · | · | · | · | · | · | · | |
| Other Current Assets | $39M | $62M | $116M | $68M | $121M | $119M | $64M | $122M | $120M | $100M | · | $108M | $101M | $113M | · | $68M | |
| Current Assets | $1.64B | $2.44B | $2.52B | $2.16B | $1.75B | $1.64B | $1.72B | $1.88B | $1.67B | $1.80B | · | $1.65B | $1.50B | $1.43B | · | $1.21B | |
| PP&E (Net) | $90M | $91M | $90M | $97M | $92M | $87M | $83M | $80M | $80M | $75M | · | $69M | $66M | $63M | · | $61M | |
| PP&E (Gross) | · | · | $208M | · | · | · | $189M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $118M | · | · | · | $106M | · | · | · | · | · | · | · | · | · | |
| Goodwill | $501M | · | · | · | · | · | · | $6M | $6M | $6M | · | $6M | $6M | $6M | $5M | · | |
| Intangibles | $2.23B | · | · | $36M | $37M | $36M | · | $34M | $34M | $34M | · | $35M | $37M | $37M | · | · | |
| Other Non-current Assets | $59M | $74M | $60M | $20M | $22M | $15M | $52M | $62M | $58M | $51M | · | $43M | $36M | $25M | · | $10M | |
| Total Assets | $5.36B | $4.91B | $4.63B | $4.27B | $3.89B | $3.69B | $3.72B | $3.54B | $3.31B | $3.47B | · | $2.85B | $2.61B | $2.36B | · | $2.14B | |
| Accounts Payable | $808M | $773M | $674M | $584M | $490M | $475M | $462M | $393M | $358M | $417M | · | $503M | $392M | $356M | · | $298M | |
| Current Liabilities | $874M | $832M | $743M | $638M | $546M | $523M | $508M | $430M | $398M | $713M | · | $692M | $582M | $374M | · | $485M | |
| Capital Leases | $402M | $406M | $415M | $428M | $439M | $448M | $455M | $251M | $256M | $253M | · | $86M | $89M | $90M | · | $97M | |
| Deferred Tax | $92M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Other Non-current Liabilities | $298M | $261M | $220M | $196M | $210M | $182M | $166M | $135M | $141M | $120M | · | $69M | $88M | $41M | · | $17M | |
| Total Liabilities | $1.67B | $1.50B | $1.38B | $1.26B | $1.20B | $1.15B | $1.13B | $816M | $796M | $1.09B | · | $846M | $760M | $675M | · | $599M | |
| Common Stock | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | · | $100.0K | $100.0K | $100.0K | · | $100.0K | |
| Retained Earnings | $724M | $590M | $448M | $294M | $84M | $-5M | $29M | $81M | $-49M | $-114M | · | $-305M | $-388M | $-483M | · | $-496M | |
| AOCI | $5M | $400.0K | $13M | $13M | $12M | $9M | $6M | $14M | $2M | $3M | · | $-2M | $-1M | $-3M | · | $-14M | |
| Stockholders' Equity | $3.69B | $3.41B | $3.25B | $3.00B | $2.69B | $2.54B | $2.59B | $2.72B | $2.51B | $2.39B | $2.23B | $2.00B | $1.85B | $1.68B | $1.71B | $1.54B | |
| Liabilities + Equity | $5.36B | $4.91B | $4.63B | $4.27B | $3.89B | $3.69B | $3.72B | $3.54B | $3.31B | $3.47B | · | $2.85B | $2.61B | $2.36B | · | $2.14B | |
| Shares Outstanding | 101,600,000 | 100,600,000 | 100,100,000 | 99,700,000 | 99,000,000 | 99,000,000 | 99,400,000 | 101,200,000 | 100,900,000 | 100,600,000 | · | 98,200,000 | 97,600,000 | 97,500,000 | · | 96,100,000 |
现金流
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $65M | $57M | $59M | $54M | $53M | $53M | $66M | $42M | $43M | $44M | $38M | $48M | $68M | $40M | $44M | $43M | |
| Amort. of Intangibles | $16M | $100.0K | $1M | $1M | $1M | $1M | $900.0K | $900.0K | $900.0K | $900.0K | $800.0K | $900.0K | $900.0K | $900.0K | $500.0K | $0 | |
| Operating Cash Flow | $136M | $146M | $388M | $228M | $102M | $65M | $242M | $158M | $65M | $130M | $124M | $212M | $180M | $-125M | $143M | $99M | |
| CapEx | $8M | $9M | $-2M | $13M | $12M | $11M | $7M | $8M | $12M | $11M | $5M | $8M | $7M | $8M | $2M | $-2M | |
| Investing Cash Flow | $-135M | $-506M | $-53M | $-197M | $-29M | $14M | $-68M | $25M | $-28M | $-55M | $-202M | $-97M | $-126M | $-42M | $-116M | $-61M | |
| Stock Issued | $85M | $24M | $37M | $46M | $14M | $32M | $10M | $26M | $16M | $70M | $35M | $19M | $3M | $8M | $25M | $11M | |
| Stock Repurchased | $12M | $54M | $0 | $0 | $18M | $150M | $300M | $0 | $0 | $0 | · | · | · | · | · | · | |
| Net Stock Activity | · | $-30M | · | · | · | $-118M | · | · | · | $70M | · | · | · | $8M | · | · | |
| Financing Cash Flow | $63M | $-86M | $37M | $46M | $-3M | $-118M | $-290M | $26M | $-293M | $70M | $35M | $19M | $3M | $8M | $25M | $11M | |
| Net Change in Cash | $64M | $-446M | $373M | $76M | $70M | $-39M | $-116M | $209M | $-257M | $145M | $-43M | $134M | $57M | $-159M | $51M | $49M | |
| Free Cash Flow | · | $137M | · | · | · | $54M | · | · | · | $119M | · | · | · | $-134M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $118M | · | · | · | $-135M | · | · |
盈利能力
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 15.8% | 23.7% | · | 30.1% | 21.2% | 4.1% | · | 29.5% | 24.6% | 19.3% | · | 28.3% | 16.3% | -27.2% | · | 22.6% | |
| Net Margin | 15.1% | 24.3% | · | 26.4% | 15.6% | 1.4% | · | 20.9% | 11.0% | 8.4% | · | 16.7% | 21.1% | -18.2% | · | 17.7% | |
| Pretax Margin | 16.9% | 30.3% | · | 36.7% | 23.2% | 2.6% | · | 30.6% | 16.7% | 6.7% | · | 23.2% | 26.9% | -24.6% | · | 25.2% | |
| EBITDA Margin | 15.8% | 23.7% | · | 30.1% | 21.2% | 4.1% | · | 29.5% | 24.6% | 19.3% | · | 28.3% | 16.3% | -27.2% | · | 22.6% | |
| ROA | 3.1% | 4.6% | · | 5.4% | 3.0% | 0.22% | · | 4.1% | 2.2% | 1.5% | · | 3.3% | 4.1% | -3.4% | · | 3.3% | |
| ROE | 4.5% | 6.7% | · | 7.3% | 4.1% | 0.32% | · | 5.5% | 3.0% | 2.1% | · | 4.7% | 5.8% | -5.0% | · | 4.7% | |
| ROIC | 3.6% | 4.5% | · | 5.7% | 3.6% | 0.50% | · | 4.6% | 3.8% | 5.2% | · | 5.1% | 3.1% | -5.0% | · | 4.0% |
流动性与偿付能力
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.9 | 2.9 | · | 3.4 | 3.2 | 3.1 | · | 4.4 | 4.2 | 2.5 | · | 2.4 | 2.6 | 3.8 | · | 2.5 | |
| Quick Ratio | 1.4 | 1.2 | · | 1.7 | 1.6 | 1.4 | · | 1.9 | 1.5 | 1.2 | · | 1.0 | 0.9 | 1.3 | · | 1.1 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | 90.3 | · | 128.4 | 56.6 | -103.8 | · | 73.2 |
效率
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | |
| Inventory Turnover | · | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.3 | 0.4 | 0.3 | · | 0.2 | |
| Receivables Turnover | 1.3 | 1.3 | · | 1.3 | 1.3 | 1.2 | · | 1.4 | 1.4 | 1.2 | · | 1.4 | 1.4 | 1.3 | · | 1.7 |
每股
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $36.35 | $33.87 | · | $30.13 | $27.22 | $25.61 | · | $26.87 | $24.87 | $23.72 | · | $20.39 | $18.99 | $17.28 | · | $16.07 | |
| Revenue / Share | $9.20 | $7.88 | · | $7.76 | $6.81 | $5.59 | · | $5.96 | $5.68 | $4.97 | · | $4.93 | $4.52 | $4.33 | · | $3.92 | |
| Cash Flow / Share | · | $1.41 | · | · | · | $0.63 | · | · | · | $1.26 | · | · | · | $-1.29 | · | · | |
| Cash / Share | $3.27 | $2.65 | · | $3.41 | $2.67 | $1.96 | · | $3.45 | $1.38 | $3.94 | · | $2.99 | $1.64 | $1.06 | · | $2.21 | |
| EPS (TTM) | $6.83 | $6.50 | · | $4.18 | $3.38 | $2.95 | · | $3.78 | $3.36 | $3.68 | · | $1.89 | $1.76 | $0.63 | · | $0.58 |
估值 (TTM)
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $3.37B | $3.10B | · | $2.68B | $2.51B | $2.41B | · | $2.24B | $2.12B | $1.98B | · | $1.78B | $1.67B | $1.60B | · | $1.39B | |
| Net Income TTM | $706M | $669M | · | $428M | $348M | $306M | · | $386M | $339M | $370M | · | $191M | $176M | $64M | · | $58M | |
| Market Cap | $17.12B | $13.25B | · | $14.00B | $12.44B | $10.95B | · | $11.66B | $13.89B | $13.87B | · | $11.05B | $9.20B | $9.87B | · | $10.21B | |
| P/E | 24.7 | 20.3 | · | 33.6 | 37.2 | 37.5 | · | 30.5 | 41.0 | 37.5 | · | 59.5 | 53.6 | 160.7 | · | 183.1 | |
| P/S | 5.1 | 4.3 | · | 5.2 | 5.0 | 4.5 | · | 5.2 | 6.6 | 7.0 | · | 6.2 | 5.5 | 6.2 | · | 7.3 | |
| P/B | 4.6 | 3.9 | · | 4.7 | 4.6 | 4.3 | · | 4.3 | 5.5 | 5.8 | · | 5.5 | 5.0 | 5.9 | · | 6.6 | |
| P / Tangible Book | 17.7 | 3.9 | · | 4.7 | 4.7 | 4.4 | · | 4.4 | 5.6 | 5.9 | · | 5.6 | 5.1 | 6.0 | · | 6.6 | |
| P / Cash Flow | · | 90.9 | · | · | · | 169.0 | · | · | · | 106.5 | · | · | · | -78.8 | · | · | |
| Earnings Yield | 4.0% | 4.9% | · | 3.0% | 2.7% | 2.7% | · | 3.3% | 2.4% | 2.7% | · | 1.7% | 1.9% | 0.62% | · | 0.55% |
最近期在左侧 · 空值显示为 ·
财务报表 损益表、资产负债表、现金流量表 — 年度，近5年
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 收入 | $2.86B | $2.36B | $1.89B | $1.49B | $1.13B |
| 营业利润率 % | 21.6% | 24.2% | 13.3% | 16.7% | 9.0% |
| 净收入 | $479M | $341M | $250M | $154M | $90M |
| 稀释后每股收益 (EPS) | $4.67 | $3.29 | $2.47 | $1.56 | $0.92 |
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 流动比率 | 3.4 | 3.4 | 2.5 | 2.7 | 4.0 |
| 速动比率 | 1.9 | 1.4 | 1.1 | 1.1 | 3.6 |
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 自由现金流 | $749M | $557M | $362M | $323M | $233M |
机构持有人 (13F) 825 家申报者 · $18.1B 总计 · 截至 2026年9月30日
在其季度SEC表格13F中报告持有此股票的机构。仅限多头头寸；单个申报人可能因单独的期权腿而出现两次。 大的抵消性看跌/看涨腿通常反映做市或对冲库存，而非方向性判断。
持有人
825
持有价值
$18.1B
新仓位
148
已退出持仓
62
机构活动 — Q2 2026 与上一季度对比
| 新仓位 | 已退出持仓 | 增加 | 减少 | 净股数变动 |
|---|---|---|---|---|
| 148 (+50 与上一季度对比) | 62 (-36 与上一季度对比) | 317 (+16 与上一季度对比) | 226 (+12 与上一季度对比) | +587K |
与Q1 2026对比。 SEC 13F表格的提交截止日期是季度末后45天，外加少量延迟提交的缓冲期——在此窗口期内的季度将被跳过，优先显示最近一个已完整报告的季度对。
| 机构 | 价值 | 股份 | % 已追踪的13F | 类型 |
|---|---|---|---|---|
| BlackRock, Inc. | $2310885707 | 13711607 | 12.75% | 股份 |
| VANGUARD GROUP INC | $1375793692 | 9700301 | 7.59% | 股份 |
| JPMORGAN CHASE & CO | $1088569109 | 6398674 | 6.01% | 股份 |
| Dodge & Cox | $941218594 | 5584707 | 5.19% | 股份 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $838307078 | 4974083 | 4.63% | 股份 |
| VANGUARD CAPITAL MANAGEMENT LLC | $766048708 | 4545339 | 4.23% | 股份 |
| STATE STREET CORP | $739126759 | 4385598 | 4.08% | 股份 |
| AQR CAPITAL MANAGEMENT LLC | $643472716 | 3818037 | 3.55% | 股份 |
| RENAISSANCE TECHNOLOGIES LLC | $393680402 | 2335897 | 2.17% | 股份 |
| GEODE CAPITAL MANAGEMENT, LLC | $359607676 | 2138777 | 1.98% | 股份 |
| TWO SIGMA INVESTMENTS, LP | $349922479 | 2076260 | 1.93% | 股份 |
| Vestal Point Capital, LP | $316845800 | 1880000 | 1.75% | 股份 |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $251858951 | 1494259 | 1.39% | 股份 |
| MORGAN STANLEY | $222231858 | 1318607 | 1.23% | 股份 |
| RTW INVESTMENTS, LP | $213689740 | 1267925 | 1.18% | 股份 |
| NORTHERN TRUST CORP | $212306405 | 1259717 | 1.17% | 股份 |
| Invesco Ltd. | $181565621 | 1077317 | 1.00% | 股份 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $164200136 | 974279 | 0.91% | 股份 |
| NORGES BANK | $164132866 | 973880 | 0.91% | 股份 |
| FIRST TRUST ADVISORS LP | $155578851 | 923125 | 0.86% | 股份 |
| DIMENSIONAL FUND ADVISORS LP | $123525529 | 732877 | 0.68% | 股份 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $122375286 | 726112 | 0.68% | 股份 |
| TWO SIGMA ADVISERS, LP | $119504823 | 842592 | 0.66% | 股份 |
| Bank of New York Mellon Corp | $117826993 | 699125 | 0.65% | 股份 |
| Swedbank AB | $109730107 | 651082 | 0.61% | 股份 |
| VANGUARD FIDUCIARY TRUST CO | $109170737 | 647763 | 0.60% | 股份 |
| IEQ CAPITAL, LLC | $107913614 | 640304 | 0.60% | 股份 |
| GOLDMAN SACHS GROUP INC | $106495877 | 631892 | 0.59% | 股份 |
| BANK OF AMERICA CORP /DE/ | $104382489 | 619352 | 0.58% | 股份 |
| VICTORY CAPITAL MANAGEMENT INC | $104238729 | 618499 | 0.58% | 股份 |
| Man Group plc | $101292738 | 601019 | 0.56% | 股份 |
| ROYAL BANK OF CANADA | $98337000 | 583476 | 0.54% | 股份 |
| RAYMOND JAMES FINANCIAL INC | $97778953 | 580170 | 0.54% | 股份 |
| FRANKLIN RESOURCES INC | $93211316 | 553068 | 0.51% | 股份 |
| UBS Group AG | $92009492 | 545937 | 0.51% | 股份 |
| Caisse de depot et placement du Quebec | $91002327 | 539961 | 0.50% | 股份 |
| ARMISTICE CAPITAL, LLC | $90307457 | 535838 | 0.50% | 股份 |
| AMERIPRISE FINANCIAL INC | $84660571 | 502267 | 0.47% | 股份 |
| PRIMECAP MANAGEMENT CO/CA/ | $82807988 | 491340 | 0.46% | 股份 |
| Hood River Capital Management LLC | $79082184 | 469233 | 0.44% | 股份 |
| Nuveen, LLC | $77408341 | 459301 | 0.43% | 股份 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $75318261 | 571719 | 0.42% | 股份 |
| Pictet Asset Management Holding SA | $72751030 | 430635 | 0.40% | 股份 |
| Rockefeller Capital Management L.P. | $62955982 | 373548 | 0.35% | 股份 |
| Fiera Capital Corp | $62895914 | 373192 | 0.35% | 股份 |
| Gotham Asset Management, LLC | $62622213 | 371568 | 0.35% | 股份 |
| JANUS HENDERSON GROUP PLC | $61515240 | 466977 | 0.34% | 股份 |
| ALLIANCEBERNSTEIN L.P. | $60767710 | 461270 | 0.34% | 股份 |
| Vinva Investment Management Ltd | $58838530 | 346109 | 0.32% | 股份 |
| AustralianSuper Pty Ltd | $58817535 | 348993 | 0.32% | 股份 |
激进投资者及 5%+ 股东 1 持仓
提交了 SEC Schedule 13D 的投资者 — 持有超过 5% 的受益所有权，意图影响发行人（激进股东持股、董事会活动、并购）。每一行显示该申报人持仓的最新已知状态。
| 申报人 | 已申报 | 持股 | 状态 | 目的 | 申报 |
|---|---|---|---|---|---|
| Neurocrine Biosciences, Inc. ×3 申报 | 2023年2月24日 | · | 初始申报 | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
公司内部人士 41 位内幕人士 · 22 位高管 · 15 位董事
| 内部人士 | 角色 | 上次活动 | 持股数量 | 买入 12个月 | 卖出 12个月 | 净额 12个月 |
|---|---|---|---|---|---|---|
| Kyle Gano | Chief Executive Officer | 2026年9月11日 F | 154728 | 0 | 3 | $-4872890 |
| Matt Abernethy | Chief Financial Officer | 2026年9月14日 S | 42808 | 0 | 1 | $-363289 |
| Timothy Coughlin | Chief Financial Officer | 2017年2月6日 S | 137961 | 0 | 0 | $0 |
| David-Alexandre C Gros | President & COO | 2017年2月6日 A | · | 0 | 0 | $0 |
| David W. Boyer | Chief Corp. Affairs Officer | 2026年9月14日 S | 8722 | 0 | 2 | $-739070 |
| Ingrid Delaet | Chief Regulatory Officer | 2026年9月11日 F | 18289 | 0 | 5 | $-3747962 |
| Jude Onyia | Chief Scientific Officer | 2026年9月11日 F | 22647 | 0 | 2 | $-3473580 |
| Sanjay Chandru Keswani | Chief Medical Officer | 2026年9月11日 F | 3281 | 0 | 0 | $0 |
| Julie Cooke | Chief Human Resources Officer | 2026年9月11日 F | 24025 | 0 | 5 | $-5770377 |
| Eric Benevich | Chief Commercial Officer | 2026年9月11日 F | 67297 | 0 | 2 | $-1238918 |
| Darin Lippoldt | Chief Legal Officer | 2026年9月11日 F | 56793 | 0 | 5 | $-4196071 |
| Eiry Roberts | Chief Medical Officer | 2025年2月13日 M | 35640 | 0 | 0 | $0 |
| Malcolm Lloyd-Smith | Chief Integration Officer | 2023年2月8日 S | 42337 | 0 | 0 | $0 |
| Dimitri E. Grigoriadis | Chief Research Officer | 2022年1月31日 A | 82273 | 0 | 0 | $0 |
| Haig P. Bozigian | Chief Development Officer | 2021年2月8日 A | 157651 | 0 | 0 | $0 |
| Christopher Flint Obrien | Former Chief Medical Officer | 2018年2月5日 A | 55946 | 0 | 0 | $0 |
| VALEUR JENSEN MARGARET E | EVP and General Counsel | 2011年8月31日 A | 118256 | 0 | 0 | $0 |
| Richard J Ranieri | Sr. VP, Human Resources | 2008年2月27日 A | 9667 | 0 | 0 | $0 |
| Wendall Wierenga | EVP, Research & Development | 2006年1月19日 A | 5023 | 0 | 0 | $0 |
| Henry Pan | Executive VP and CMO | 2005年6月3日 A | 11216 | 0 | 0 | $0 |
| Robert J Little | SVP, Commercial Operations | 2005年2月18日 A | · | 0 | 0 | $0 |
| SAUNDERS JOHN | Vice President Research (Chem) | 2003年12月18日 S | 7966 | 0 | 0 | $0 |
| Kevin Charles Gorman | 董事 | 2026年9月11日 F | 517797 | 0 | 1 | $-37824431 |
| SHERWIN STEPHEN A | 董事 | 2026年9月2日 G | 14860 | 0 | 5 | $-4132990 |
| Leslie V Norwalk | 董事 | 2026年7月29日 M | 2430 | 0 | 5 | $-1973882 |
| Johanna Mercier | 董事 | 2026年5月27日 A | 6853 | 0 | 0 | $0 |
| William H Rastetter | 董事 | 2026年5月27日 A | 43678 | 0 | 1 | $-2732760 |
| Christine A Poon | 董事 | 2026年5月27日 A | 4753 | 0 | 0 | $0 |
| POPS RICHARD F | 董事 | 2026年5月27日 A | 37798 | 0 | 1 | $-2364750 |
| LYONS GARY A | 董事 | 2026年5月27日 A | 122141 | 0 | 1 | $-2289150 |
| MORROW GEORGE J | 董事 | 2026年5月27日 A | 10386 | 0 | 1 | $-2150550 |
| Alfred Sandrock | 董事 | 2019年5月22日 A | · | 0 | 0 | $0 |
| Corinne H Nevinny | 董事 | 2018年5月24日 A | 43283 | 0 | 0 | $0 |
| Thomas W Mitchell | 董事 | 2015年5月28日 A | 1000 | 0 | 0 | $0 |
| VALE WYLIE W | 董事 | 2011年5月25日 A | 231372 | 0 | 0 | $0 |
| Adrian Adams | 董事 | 2006年6月30日 A | · | 0 | 0 | $0 |
| Shalini Sharp | · | 2026年5月27日 A | 4088 | 0 | 0 | $0 |
| MOLLICA JOSEPH A | · | 2017年5月22日 A | 56042 | 0 | 0 | $0 |
| HAWRAN PAUL W | · | 2006年9月18日 J | 132000 | 0 | 0 | $0 |
| Lawrence Steinman | · | 2005年3月2日 S | 15500 | 0 | 0 | $0 |
| CONLON PAUL J | · | 2003年12月16日 S | 57335 | 0 | 0 | $0 |
来自SEC表格3/4/5申报的内部人士；净额=仅公开市场买卖
ETF持仓 由 104 只交易所交易基金持有
权重仅反映直接股权持仓（N-PORT）；杠杆基金或基于衍生品的基金可能持有未显示的额外掉期敞口。
| 基金 | 权重 | 单位 | 截至 | 来源 |
|---|---|---|---|---|
| IBRN · iShares Trust | 3.75% | 1793 SH | 2026年9月11日 | 每日 |
| PBE · Invesco Exchange-Traded Fund Trust | 2.60% | 76511 SH | 2026年10月2日 | 每日 |
| MCOW · Pacer Funds Trust | 2.57% | 164 NS | 2026年7月31日 | N-PORT |
| BUL · Pacer Funds Trust | 2.15% | 16896 NS | 2026年7月31日 | N-PORT |
| CVSM · Elevation Series Trust | 2.04% | 11525 NS | 2026年7月31日 | N-PORT |
| JMID · Janus Detroit Street Trust | 1.93% | 2742 NS | 2026年7月31日 | N-PORT |
| POWA · Invesco Exchange-Traded Self-Inde... | 1.92% | 22570 SH | 2026年10月2日 | 每日 |
| FGSI · First Trust Exchange-Traded Fund IV | 1.90% | 236 NS | 2026年7月31日 | N-PORT |
| ABOT · Abacus FCF ETF Trust | 1.90% | 460 NS | 2026年7月31日 | N-PORT |
| XMHQ · Invesco Exchange-Traded Fund Trust | 1.74% | 667222 SH | 2026年10月2日 | 每日 |
| FXH · First Trust Exchange-Traded Alpha... | 1.67% | 105135 NS | 2026年7月31日 | N-PORT |
| GRPM · Invesco Exchange-Traded Fund Trust | 1.61% | 56862 SH | 2026年10月2日 | 每日 |
| BBP · ETFis Series Trust I | 1.44% | 8494 NS | 2026年7月31日 | N-PORT |
| CSMD · Professionally Managed Portfolios | 1.18% | 32094 NS | 2026年7月31日 | N-PORT |
| IBB · iShares Trust | 1.14% | 755021 SH | 2026年9月11日 | 每日 |
| AGRW · ALLSPRING EXCHANGE-TRADED FUNDS T... | 1.11% | 7516 NS | 2026年7月31日 | N-PORT |
| JSMD · Janus Detroit Street Trust | 1.05% | 66455 NS | 2026年7月31日 | N-PORT |
| RFG · Invesco Exchange-Traded Fund Trust | 1.04% | 24859 SH | 2026年10月2日 | 每日 |
| IBBQ · Invesco Exchange-Traded Fund Trus... | 0.96% | 7190 SH | 2026年10月2日 | 每日 |
| IVOG · VANGUARD ADMIRAL FUNDS | 0.89% | 99214 SH | 2026年8月19日 | 每日 |
| COWG · Pacer Funds Trust | 0.78% | 103520 NS | 2026年7月31日 | N-PORT |
| JDOC · J.P. Morgan Exchange-Traded Fund ... | 0.73% | 399 NS | 2026年7月31日 | N-PORT |
| LSEQ · Harbor ETF Trust | 0.72% | 661 NS | 2026年7月31日 | N-PORT |
| QQQJ · Invesco Exchange-Traded Fund Trus... | 0.72% | 59939 SH | 2026年10月2日 | 每日 |
| LABU · Direxion Shares ETF Trust | 0.71% | 20978 NS | 2026年7月31日 | N-PORT |
| IQSM · New York Life Investments ETF Trust | 0.63% | 12528 NS | 2026年7月31日 | N-PORT |
| FNY · First Trust Exchange-Traded Alpha... | 0.63% | 21784 NS | 2026年7月31日 | N-PORT |
| QLV · FlexShares Trust | 0.56% | 5460 NS | 2026年7月31日 | N-PORT |
| ISCG · iShares Trust | 0.52% | 31868 SH | 2026年9月11日 | 每日 |
| PTMC · Pacer Funds Trust | 0.47% | 11072 NS | 2026年7月31日 | N-PORT |
| USMV · iShares Trust | 0.46% | 697795 SH | 2026年9月11日 | 每日 |
| VBK · VANGUARD INDEX FUNDS | 0.46% | 1331820 SH | 2026年8月19日 | 每日 |
| IVOO · VANGUARD ADMIRAL FUNDS | 0.46% | 162408 SH | 2026年8月19日 | 每日 |
| QVMM · Invesco Exchange-Traded Fund Trus... | 0.45% | 13252 SH | 2026年10月2日 | 每日 |
| SMDX · Tidal Trust III | 0.43% | 3374 NS | 2026年7月31日 | N-PORT |
| BKMC · BNY Mellon ETF Trust | 0.42% | 16429 NS | 2026年7月31日 | N-PORT |
| IWP · iShares Trust | 0.39% | 480949 SH | 2026年9月11日 | 每日 |
| SDG · iShares Trust | 0.38% | 4071 SH | 2026年9月11日 | 每日 |
| BBMC · J.P. Morgan Exchange-Traded Fund ... | 0.36% | 44021 NS | 2026年7月31日 | N-PORT |
| MIDU · Direxion Shares ETF Trust | 0.36% | 1476 NS | 2026年7月31日 | N-PORT |
| FSMD · FIDELITY COVINGTON TRUST | 0.31% | 46187 NS | 2026年7月31日 | N-PORT |
| FNX · First Trust Exchange-Traded Alpha... | 0.30% | 24447 NS | 2026年7月31日 | N-PORT |
| JPME · J.P. Morgan Exchange-Traded Fund ... | 0.29% | 8053 NS | 2026年7月31日 | N-PORT |
| COWZ · Pacer Funds Trust | 0.25% | 283150 NS | 2026年7月31日 | N-PORT |
| IYH · iShares Trust | 0.25% | 57843 SH | 2026年9月11日 | 每日 |
| VHT · VANGUARD WORLD FUND | 0.24% | 286599 SH | 2026年8月19日 | 每日 |
| FHLC · FIDELITY COVINGTON TRUST | 0.23% | 45259 NS | 2026年7月31日 | N-PORT |
| SMMD · iShares Trust | 0.21% | 52744 SH | 2026年9月11日 | 每日 |
| EUSA · iShares, Inc. | 0.20% | 25089 SH | 2026年9月11日 | 每日 |
| VB · VANGUARD INDEX FUNDS | 0.20% | 2306077 SH | 2026年8月19日 | 每日 |
| PWS · Pacer Funds Trust | 0.20% | 287 NS | 2026年7月31日 | N-PORT |
| SIZE · iShares Trust | 0.20% | 5417 SH | 2026年9月11日 | 每日 |
| VXF · VANGUARD INDEX FUNDS | 0.19% | 1153763 SH | 2026年8月19日 | 每日 |
| FAD · First Trust Exchange-Traded Alpha... | 0.19% | 6541 NS | 2026年7月31日 | N-PORT |
| ACWV · iShares, Inc. | 0.18% | 37854 SH | 2026年9月11日 | 每日 |
| RWK · Invesco Exchange-Traded Fund Trus... | 0.13% | 11381 SH | 2026年10月2日 | 每日 |
| IWR · iShares Trust | 0.11% | 405396 SH | 2026年9月11日 | 每日 |
| FHEQ · Fidelity Greenwood Street Trust | 0.11% | 6157 NS | 2026年7月31日 | N-PORT |
| ESUM · Strategy Shares | 0.10% | 1133 NS | 2026年7月31日 | N-PORT |
| HEQQ · J.P. Morgan Exchange-Traded Fund ... | 0.10% | 177 NS | 2026年7月31日 | N-PORT |
| LRND · New York Life Investments ETF Trust | 0.10% | 2270 NS | 2026年7月31日 | N-PORT |
| HELO · J.P. Morgan Exchange-Traded Fund ... | 0.09% | 23838 NS | 2026年7月31日 | N-PORT |
| EQAL · Invesco Exchange-Traded Fund Trus... | 0.09% | 4828 SH | 2026年10月2日 | 每日 |
| DFUV · Dimensional ETF Trust | 0.08% | 70759 NS | 2026年7月31日 | N-PORT |
| OMFL · Invesco Exchange-Traded Self-Inde... | 0.07% | 23598 SH | 2026年10月2日 | 每日 |
| DYNF · BlackRock ETF Trust | 0.07% | 177312 SH | 2026年9月11日 | 每日 |
| USXF · iShares Trust | 0.06% | 5665 SH | 2026年9月11日 | 每日 |
| ESMV · iShares Trust | 0.05% | 26 SH | 2026年9月11日 | 每日 |
| GARP · iShares Trust | 0.05% | 9869 SH | 2026年9月11日 | 每日 |
| DFAC · Dimensional ETF Trust | 0.05% | 141631 NS | 2026年7月31日 | N-PORT |
| DXUV · Dimensional ETF Trust | 0.05% | 1484 NS | 2026年7月31日 | N-PORT |
| DCOR · Dimensional ETF Trust | 0.04% | 8569 NS | 2026年7月31日 | N-PORT |
| IUSG · iShares Trust | 0.04% | 89338 SH | 2026年9月11日 | 每日 |
| IWF · iShares Trust | 0.04% | 320069 SH | 2026年9月11日 | 每日 |
| VONG · VANGUARD SCOTTSDALE FUNDS | 0.04% | 134662 SH | 2026年8月19日 | 每日 |
| ESGV · VANGUARD WORLD FUND | 0.03% | 22375 SH | 2026年8月19日 | 每日 |
| TILT · FlexShares Trust | 0.03% | 3888 NS | 2026年7月31日 | N-PORT |
| DFAU · Dimensional ETF Trust | 0.03% | 20775 NS | 2026年7月31日 | N-PORT |
| RECS · Columbia ETF Trust I | 0.02% | 8549 NS | 2026年7月31日 | N-PORT |
| DFUS · Dimensional ETF Trust | 0.02% | 28885 NS | 2026年7月31日 | N-PORT |
| IYY · iShares Trust | 0.02% | 4355 SH | 2026年9月11日 | 每日 |
| IWB · iShares Trust | 0.02% | 68459 SH | 2026年9月11日 | 每日 |
| ITOT · iShares Trust | 0.02% | 131068 SH | 2026年9月11日 | 每日 |
| IWS · iShares Trust | 0.02% | 20508 SH | 2026年9月11日 | 每日 |
| IWV · iShares Trust | 0.02% | 27012 SH | 2026年9月11日 | 每日 |
| PBUS · Invesco Exchange-Traded Fund Trus... | 0.02% | 16531 SH | 2026年10月2日 | 每日 |
| VTI · VANGUARD INDEX FUNDS | 0.02% | 3193839 SH | 2026年8月19日 | 每日 |
| VONE · VANGUARD SCOTTSDALE FUNDS | 0.02% | 16227 SH | 2026年8月19日 | 每日 |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.02% | 8342 SH | 2026年8月19日 | 每日 |
| PRF · Invesco Exchange-Traded Fund Trust | 0.02% | 11591 SH | 2026年10月2日 | 每日 |
| TOK · iShares Trust | 0.02% | 249 SH | 2026年9月11日 | 每日 |
| URTH · iShares, Inc. | 0.02% | 8440 SH | 2026年9月11日 | 每日 |
| ACWI · iShares Trust | 0.01% | 30548 SH | 2026年9月11日 | 每日 |
| DFLV · Dimensional ETF Trust | 0.01% | 4926 NS | 2026年7月31日 | N-PORT |
| DFVX · Dimensional ETF Trust | 0.01% | 323 NS | 2026年7月31日 | N-PORT |
| VT · VANGUARD INTERNATIONAL EQUITY IND... | 0.01% | 85082 SH | 2026年8月19日 | 每日 |
| VONV · VANGUARD SCOTTSDALE FUNDS | 0.01% | 8319 SH | 2026年8月19日 | 每日 |
| FYEE · Fidelity Greenwood Street Trust | 0.01% | 110 NS | 2026年7月31日 | N-PORT |
| REVS · Columbia ETF Trust I | 0.01% | 124 NS | 2026年7月31日 | N-PORT |
| IWD · iShares Trust | 0.01% | 30627 SH | 2026年9月11日 | 每日 |
| IJH · iShares Trust | · | 3528125 SH | 2026年9月11日 | 每日 |
| IJK · iShares Trust | · | 582451 SH | 2026年9月11日 | 每日 |
| XJH · iShares Trust | · | 13736 SH | 2026年9月8日 | 每日 |
| ISCB · iShares Trust | · | 4526 SH | 2026年9月11日 | 每日 |
NBIX 分析师共识 看涨和看跌分析师观点、12个月价格目标、上涨空间
评级 · 36 位分析师
买入
中位数目标
$214.00
+49.5%
14 38.9%
强烈买入
17 47.2%
买入
5 13.9%
持有
0 0.0%
卖出
0 0.0%
强烈卖出
12个月价格目标
29 位分析师 · 2026-10-03平均目标 $207.81 +45.1%
← 低于所有目标
当前价格 $143.18
最低$164.00
平均值$207.81
最高$253.00
同行比较（GICS 子行业） 关键指标与行业同行对比
财年依据，价格截至各公司上一个财年末收盘价。
| 股票代码 | 市值 | P/E | 营收同比增长 | 净利润率 | ROE | 毛利率 |
|---|---|---|---|---|---|---|
| NBIX | $14.20B | 30.4 | 21.4% | 16.7% | 16.1% | · |
| INSM | $37.29B | -27.1 | 66.7% | -210.5% | -128.4% | · |
| INCY | $19.60B | 15.4 | 21.2% | 25.0% | 27.6% | · |
| UTHR | $21.27B | 17.5 | 10.6% | 41.9% | 18.7% | 87.9% |
| EXEL | $11.44B | 15.7 | 7.0% | 33.7% | 37.3% | · |
| SMMT | $13.56B | -12.1 | · | · | -235.1% | · |
| BBIO | $14.90B | -20.2 | 126.3% | -146.0% | 41.2% | · |
| TWST | $1.71B | -21.6 | 20.3% | -20.6% | -17.0% | · |
| HALO | $7.93B | 26.3 | 37.5% | 22.7% | 166.1% | · |
| MDGL | $13.30B | -45.3 | 432.1% | -30.1% | -44.4% | · |
最新新闻 提及该公司的近期头条新闻
交易信号 近期买入/卖出信号，包含入场价和风险/回报比
BLUECHIP_DIP
止损出局
风险 1
奖励 1.67
入场
$156.04
R:R 1.67
BLUECHIP_DIP
止损出局
风险 1
奖励 2.78
入场
$161.50
R:R 2.78
BLUECHIP_DIP
已过期
风险 1
奖励 5.00
入场
$129.88
R:R 5.00
BLUECHIP_DIP
止损出局
风险 1
奖励 4.80
入场
$132.67
R:R 4.80
BLUECHIP_DIP
止损出局
风险 1
奖励 5.00
入场
$132.79
R:R 5.00
目前没有公开信号 — 没有卡片被填写，这是诚实的。
我的指标 您的个人关注列表 — 来自完整基本面的选定行
选择对您重要的指标 — 点击上方完整基本面中任意行的 + 号。
您的选择已保存，并会跟随您浏览所有股票。
来源：SEC 10-Q 于 七月 31, 2026 申报